Analysis Group Researchers Invited to Present at Major Health Care Payer Conference

February 14, 2014

Researchers from Analysis Group's Health Care Consulting practice have been invited to present at the Academy of Managed Care Pharmacy's (AMCP) 26th Annual Meeting & Expo, convening April 1 in Tampa, Florida. Our professionals will deliver 11 poster presentations on a number of medical conditions, including menopause, prescription drug abuse, lung cancer, and schizophrenia. 

Poster Presentations 

Clinical and Economic Burden of Vasomotor Symptoms among Untreated Menopausal Women, coauthored by an Analysis Group team including Vice President Patrick Lefebvre, Senior Economist Marie-Hélène Lafeuille, Economists Amanda Grittner and Jonathan Fortier, and Managing Principal and Chief Epidemiologist Mei Sheng Duh, along with researchers from Yale University's School of Medicine, Noven Pharmaceuticals, and Columbus Center for Women's Health Research. 

Clinical and Economic Impact for Women with Vasomotor Symptoms of Receiving Lower- versus Higher-Dose Paroxetine, coauthored by an Analysis Group team including Mr. Lefebvre, Ms. Lafeuille, Ms. Grittner, Mr. Fortier, and Dr. Duh, along with researchers from Yale University's School of Medicine, Noven Pharmaceuticals, and Columbus Center for Women's Health Research. 

Factors Associated with Performance on HEDIS Continuity of Antipsychotic Medications for Treatment of Schizophrenia, coauthored by an Analysis Group team including Ms. Lafeuille, Vice President Christian Frois, Economist Michel Cloutier, Dr. Duh, and Mr. Lefebvre, along with researchers from Janssen Scientific Affairs. 

Severity, Health Care Resource Use, and Costs of Patients Diagnosed with Hidradenitis Suppurativa in the United States: Evidence from a Large Administrative Claims Database, coauthored by an Analysis Group team including Vice President Annie Guérin, along with researchers from AbbVie Inc.  

Brain Metastases in Patients with ALK+ Non--Small Cell Lung Cancer: Treatment Patterns and Economic Burden, coauthored by an Analysis Group team including Associate Alex Macalalad, Economists Katherine Dea and Roy Nitulescu, and Ms. Guérin, along with researchers from Novartis Pharmaceuticals.

Treatment and Costs Post-Crizotinib Monotherapy in Patients with ALK+ Non--Small Cell Lung Cancer: A Retrospective Claims Database Analysis, coauthored by an Analysis Group team including Ms. Guérin, Ms. Dea, Mr. Nitulescu, and Dr. Macalalad, along with researchers from Novartis Pharmaceuticals.

The Economic Burden of Gastrointestinal Stromal Tumor (GIST) Recurrence in Patients Who Received Adjuvant Imatinib Therapy, coauthored by an Analysis Group team including Ms. Guérin and Economist Maryia Zhdanava, along with researchers from Novartis Pharmaceuticals. 

Characteristics of High-Cost Patients Diagnosed with Opioid Abuse, coauthored by an Analysis Group team including Managers Brad Rice and Noam Kirson, Senior Analyst Katharine Bodnar, Associate Amie Shei, and Principal Howard Birnbaum, along with researchers from Purdue Pharma L.P.  

Opioid Utilization and Abuse Rates Following the Introduction of an Abuse-Deterrent Formulation, coauthored by an Analysis Group team including Dr. Kirson, Dr. Shei, and Dr. Birnbaum, along with researchers from Purdue Pharma L.P. 

Estimating the Prevalence and Health Care Costs of Diagnosed Opioid Abuse in a Large Commercial Claims Database, coauthored by an Analysis Group team including Dr. Rice, Dr. Kirson, Dr. Shei, Analyst CJ Enloe, Senior Analyst Alice Kate Cummings, and Dr. Birnbaum, along with researchers from Purdue Pharma L.P. 

Cost-Effectiveness of Biologic Therapies for the Treatment of Moderate to Severe Psoriasis in the United States, coauthored by an Analysis Group team including Vice President James Signorovitch, Managing Principal Eric Wu, and Manager Keith Betts, along with researchers from AbbVie Inc.